


## RECENT ADVANCES AGAINST BLOOD CANCERS

In the 12 months from August 1, 2020 to July 31, 2021, the U.S. Food and Drug Administration made numerous decisions that are transforming the lives of patients with a wide array of hematologic cancers, including the following:



### **Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL)**

- Asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) is a component of a multi-agent chemotherapeutic regimen, for the treatment of those who have developed hypersensitivity to E. coli-derived asparaginase, that was approved in June 2021.

### **Acute Myeloid Leukemia**

- Azacitidine (Onureg) is an epigenome-modifying agent approved in September 2020.

### **Anaplastic Large Cell Lymphoma**

- Crizotinib (Xalkori) is a molecularly targeted therapeutic approved in January 2021.

### **Large B-cell Lymphoma**

- Lisocabtagene maraleucel (Breyanzi) is an immunotherapeutic approved in February 2021.
- Loncastuximab tesirine-lpyl (Zynlonta) is a molecularly targeted therapeutic approved in April 2021.

### **Follicular Lymphoma**

- Umbralisib (Ukoniq) is a molecularly targeted therapeutic approved in February 2021.
- Axicabtagene ciloleucel (Yescarta) is an immunotherapeutic approved in March 2021.

### **Marginal Zone Lymphoma**

- Umbralisib (Ukoniq) is a molecularly targeted therapeutic approved in February 2021.

### **Mast Cell Leukemia**

- Avapritinib (Ayvakit) is a molecularly targeted therapeutic approved in June 2021.

### **Multiple Myeloma**

- Belantamab mafodotin-blmf (Blenrep) is a molecularly targeted therapeutic approved in August 2020.
- Melphalan flufenamide (Pepaxto) is a chemotherapeutic approved in February 2021.
- Idecabtagene vicleucel (Abecma) is an immunotherapeutic approved in March 2021.